- Home
- FTDR vs BLTE Comparison
FTDR vs BLTE Comparison
Compare FTDR & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FTDR | BLTE |
|---|---|---|
| Founded | 1971 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 4.1B |
| IPO Year | 2018 | 2022 |
Fundamental Metrics
Financial Performance| Metric | FTDR | BLTE |
|---|---|---|
| Price | $58.93 | $169.05 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | $59.75 | ★ $161.57 |
| AVG Volume (30 Days) | ★ 494.9K | 237.7K |
| Earning Date | 02-26-2026 | 03-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 15.41 | N/A |
| EPS | ★ 3.46 | N/A |
| Revenue | ★ $2,042,000,000.00 | N/A |
| Revenue This Year | $15.25 | N/A |
| Revenue Next Year | $5.74 | N/A |
| P/E Ratio | $17.29 | ★ N/A |
| Revenue Growth | ★ 11.77 | N/A |
| 52 Week Low | $35.61 | $49.00 |
| 52 Week High | $70.14 | $174.78 |
Technical Indicators
Market Signals| Indicator | FTDR | BLTE |
|---|---|---|
| Relative Strength Index (RSI) | 51.36 | 64.28 |
| Support Level | $58.25 | $156.52 |
| Resistance Level | $61.72 | $171.63 |
| Average True Range (ATR) | 1.83 | 8.88 |
| MACD | -0.22 | 0.26 |
| Stochastic Oscillator | 39.98 | 79.00 |
Price Performance
Historical ComparisonAbout FTDR Frontdoor Inc.
Frontdoor Inc is a United States-based company that provides home service plans. It owns multiple home service brands including American Home Shield, HSA, OneGuard, and Landmark brands. Through its home service plans, the company helps its customers maintain their homes and protect against costly and unexpected breakdowns of essential home systems and appliances.
About BLTE Belite Bio Inc
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.